Axsome Therapeutics, Inc

AXSM Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
AXSM Income Statement
AXSM Balance Sheet
AXSM Cash Flow
Congress Trading

Recent trades of AXSM by members of U.S. Congress

Politician Type Traded
Chris Jacobs House / R Purchase $15,001 - $50,000 Jun. 16, 2022
AXSM Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
AXSM Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
AXSM Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by AXSM's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
Corporate Lobbying

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Pharmaceutical compositions comprising meloxicam Oct. 29, 2024
  • Patent Title: Use of reboxetine to treat narcolepsy Oct. 15, 2024
  • Patent Title: Dosage forms and methods for enantiomerically enriched or pure bupropion Oct. 01, 2024
  • Patent Title: Pharmaceutical compositions comprising meloxicam Jun. 11, 2024
  • Patent Title: Pharmaceutical compositions comprising meloxicam Jun. 04, 2024
  • Patent Title: Compositions for delivery of reboxetine Apr. 16, 2024
  • Patent Title: Pharmaceutical compositions comprising meloxicam Apr. 02, 2024
  • Patent Title: Reboxetine to treat narcolepsy Jan. 30, 2024
  • Patent Title: Pharmaceutical compositions comprising meloxicam Jan. 09, 2024
  • Patent Title: Pharmaceutical compositions comprising meloxicam Nov. 28, 2023
  • Patent Title: Pharmaceutical compositions comprising meloxicam Nov. 28, 2023
  • Patent Title: Pharmaceutical compositions comprising meloxicam Nov. 07, 2023
  • Patent Title: Pharmaceutical compositions comprising meloxicam Oct. 31, 2023
  • Patent Title: Dosage forms and methods for enantiomerically enriched or pure bupropion Oct. 17, 2023
  • Patent Title: Pharmaceutical compositions comprising meloxicam Sep. 19, 2023
  • Patent Title: Pharmaceutical compositions comprising meloxicam Aug. 29, 2023
  • Patent Title: Pharmaceutical compositions comprising meloxicam Aug. 01, 2023
  • Patent Title: Dosage forms and methods for enantiomerically enriched or pure bupropion May. 30, 2023
  • Patent Title: Pharmaceutical compositions comprising meloxicam Apr. 18, 2023
  • Patent Title: Pharmaceutical compositions comprising meloxicam Apr. 04, 2023
  • Patent Title: Pharmaceutical compositions comprising meloxicam Apr. 04, 2023
  • Patent Title: Pharmaceutical compositions comprising meloxicam Apr. 04, 2023
  • Patent Title: Pharmaceutical compositions comprising meloxicam Mar. 21, 2023
  • Patent Title: Pharmaceutical compositions comprising meloxicam Mar. 14, 2023
  • Patent Title: Pharmaceutical compositions comprising meloxicam Feb. 07, 2023
  • Patent Title: Pharmaceutical compositions comprising meloxicam Nov. 29, 2022
  • Patent Title: Pharmaceutical compositions comprising meloxicam Nov. 22, 2022
  • Patent Title: Pharmaceutical compositions comprising meloxicam Oct. 18, 2022
  • Patent Title: Pharmaceutical compositions comprising meloxicam Oct. 18, 2022
  • Patent Title: Pharmaceutical compositions comprising meloxicam Sep. 06, 2022
  • Patent Title: Pharmaceutical compositions comprising meloxicam Sep. 06, 2022
  • Patent Title: Dosage forms and methods for enantiomerically enriched or pure bupropion Sep. 06, 2022
  • Patent Title: Pharmaceutical compositions comprising meloxicam Aug. 30, 2022
  • Patent Title: Pharmaceutical compositions comprising meloxicam Jun. 28, 2022
  • Patent Title: Use of reboxetine to treat narcolepsy Jun. 21, 2022
  • Patent Title: Pharmaceutical compositions comprising meloxicam Jun. 14, 2022
  • Patent Title: Use of reboxetine to treat narcolepsy Jun. 07, 2022
  • Patent Title: Dosage forms and methods for enantiomerically enriched or pure bupropion May. 31, 2022
  • Patent Title: Dosage forms and methods for enantiomerically enriched or pure bupropion May. 31, 2022
  • Patent Title: Pharmaceutical compositions comprising meloxicam May. 17, 2022
  • Patent Title: Dosage forms and methods for enantiomerically enriched or pure bupropion May. 17, 2022
  • Patent Title: Pharmaceutical compositions comprising meloxicam Mar. 29, 2022
  • Patent Title: Pharmaceutical compositions comprising meloxicam Mar. 29, 2022
  • Patent Title: Pharmaceutical compositions comprising meloxicam Mar. 29, 2022
  • Patent Title: Pharmaceutical compositions comprising meloxicam Mar. 08, 2022
  • Patent Title: Pharmaceutical compositions comprising meloxicam Jan. 11, 2022
  • Patent Title: Pharmaceutical compositions comprising meloxicam Dec. 28, 2021
  • Patent Title: Pharmaceutical compositions comprising meloxicam Dec. 28, 2021
  • Patent Title: Pharmaceutical compositions comprising meloxicam Nov. 30, 2021
  • Patent Title: Use of reboxetine to treat narcolepsy Nov. 30, 2021
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of AXSM in WallStreetBets Daily Discussion

AXSM News

Recent insights relating to AXSM

CNBC Recommendations

Recent picks made for AXSM stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in AXSM

AXSM Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view AXSM Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top